Table 11

Reduction in 10-year risk of major CVD endpoints (CHD death/non-fatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n = 16,032)

Study (ref.)CVDStatin dose and comparatorRisk reduction (%)Relative risk reduction (%)Absolute risk reduction (%)LDL cholesterol reduction (mg/dl)LDL cholesterol reduction (%)
4S-DM (215)Simvastatin 20–40 mg vs. placebo85.7 to 43.25042.5186 to 11936
ASPEN 2° (220)Atorvastatin 10 mg vs. placebo39.5 to 24.53415112 to 7929
HPS-DM (216)Simvastatin 40 mg vs. placebo43.8 to 36.3177.5123 to 8431
CARE-DM (217)Pravastatin 40 mg vs. placebo40.8 to 35.4135.4136 to 9927
TNT-DM (218)Atorvastatin 80 mg vs. 10 mg26.3 to 21.6184.799 to 7722
HPS-DM (216)Simvastatin 40 mg vs. placebo17.5 to 11.5346.0124 to 8631
CARDS (221)Atorvastatin 10 mg vs. placebo11.5 to 7.5354118 to 7140
ASPEN 1° (220)Atorvastatin 10 mg vs. placebo9.8 to 7.9191.9114 to 8030
ASCOT-DM (219)Atorvastatin 10 mg vs. placebo11.1 to 10.280.9125 to 8234
  • Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and nonfatal MI. In this tabulation, results of the statin on 10-year risk of major CVD endpoints (CHD death/nonfatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, PharmD, Oregon Health & Science University, 2007.